Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | CHRNG | P07510 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRND | Q07001 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067375 | 0.82 | MAOB (0.52) | MAOBMAOASLC6A3KDM1ARCOR1 | |
| SCHEMBL3052073 | 0.80 | KDM1A (0.47) | MAOBMAOAKDM1A | |
| SCHEMBL1650476 | 0.71 | MAOB (0.54) | MAOBMAOASLC6A3KDM1ARCOR1 | |
| SCHEMBL11487632 | 0.69 | CYP2D6 (0.49) | CCR2 | |
| SCHEMBL23001568 | 0.69 | MAOB (0.39) | MAOBMAOASLC6A3 | |
| SCHEMBL23595661 | 0.68 | KDM1A (0.45) | SLC6A3KDM1ASLC6A4SLC6A2CHRNA1 | |
| SCHEMBL23595690 | 0.68 | KDM1A (0.45) | SLC6A3KDM1ASLC6A4SLC6A2CHRNA1 | |
| SCHEMBL23595698 | 0.68 | — | — | |
| SCHEMBL23595697 | 0.68 | — | — | |
| SCHEMBL25502573 | 0.68 | MAOB (0.43) | MAOBMAOASLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015677-A | Pyrimidinone derivatives and methods of use thereof | SCHERING CORP | 2011-04-13 | — | — | CN | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| EP-2148869-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | MAOB 1740/4885MAOA 2821/4885SLC6A3 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.